Epithelial to mesenchymal transition in the liver field: the double face of Everolimus in vitro

BACKGROUND: Everolimus (EVE), a mammalian target of rapamycin inhibitor, has been proposed as liver transplant immunosuppressive drug, gaining wide interest also for the treatment of cancer. Although an appropriate tolerance, it may induce several adverse effects, such as fibro-interstitial pneumoni...

Descripción completa

Detalles Bibliográficos
Autores principales: Masola, Valentina, Carraro, Amedeo, Zaza, Gianluigi, Bellin, Gloria, Montin, Umberto, Violi, Paola, Lupo, Antonio, Tedeschi, Umberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4570634/
https://www.ncbi.nlm.nih.gov/pubmed/26369804
http://dx.doi.org/10.1186/s12876-015-0347-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4570634/
https://www.ncbi.nlm.nih.gov/pubmed/26369804
http://dx.doi.org/10.1186/s12876-015-0347-6

Ejemplares similares